Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial.

NCT07881562 is registered in ClinicalTrials.gov with Region Skane as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07881562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial.
Lead sponsor
Region Skane
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 1, 2028
Completion date
March 31, 2031
Enrollment
1,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

Arms

As registered; 2 arms.

  • Intervention group ExperimentalEsketamine

    They will receive esketamine as an adjunct to the standard postoperative pain therapy

  • Control group Placebo comparatorPlacebo

    They will receive placebo (NaCl)

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Time weighted longitudinal postoperative pain measurement over 48 hours. From 30 minutes after awakening till 48 hours postoperative

    A time-weighted longitudinal postoperative pain measurement over 48 hours, measured using the numeric rating scale (NRS, 0-10) for pain at 30 minutes after admission to the PACU, 6, 12, 24 and 48 hours postoperatively during activity (coughing or sitting)

Lead sponsor's other trials

Region Skane, most recent start first.

Similar trials

Same condition (Endometriosis) and phase, most recent start first.